News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nanobiotix S.A. ADR
(NQ:
NBTX
)
4.975
+0.025 (+0.51%)
Streaming Delayed Price
Updated: 9:32 AM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nanobiotix S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
May 05, 2023
Good morning! We're diving into the biggest pre-market stock movers traders will want to keep an eye on for Friday morning!
Via
InvestorPlace
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
May 05, 2023
Company agreed to term sheet as of May 3, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
April 27, 2023
Via
Benzinga
Why Are Nanobiotix Shares Plummeting Today?
April 25, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 27, 2023
Via
Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 25, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 25, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 25, 2023
Via
Benzinga
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
April 24, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
April 17, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
April 11, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Earnings Scheduled For April 24, 2023
April 24, 2023
Companies Reporting Before The Bell • Dynex Cap (NYSE:DX) is estimated to report quarterly earnings at $0.17 per share on revenue of $6.99 million.
Via
Benzinga
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
March 27, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
March 14, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
February 14, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
January 11, 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
December 27, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
December 21, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
December 08, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 15, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
November 14, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients
November 10, 2022
Via
Benzinga
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
November 10, 2022
Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
November 09, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Voting Rights and Shares Capital of the Company
November 08, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
November 02, 2022
Multidisciplinary board includes twelve (12) experts from the United States and Europe that will support the development of lead therapeutic candidate NBTXR3
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
October 31, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
October 27, 2022
Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
October 18, 2022
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix: Voting Rights and Shares Capital of the Company
October 10, 2022
From
Nanobiotix
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.